China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds
The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...
Policy / Regulatory
Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance
The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...
EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns
The European Union (EU) is reportedly gearing up to launch an investigation into medical device...
FDA Advisory Committee Backs MRD as Accelerated Approval Endpoint for Multiple Myeloma
The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has...
Hainan Medical Zone Launches ‘Lecheng Global Special Medical Insurance’ for Wider Drug Access
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has launched the “Lecheng Global Special...
NHSA Reports 2023 Milestones in Basic Medical Insurance Participation and Financials
The National Healthcare Security Administration (NHSA) has published its annual “Healthcare Security Development Statistical Bulletin”...
BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...
Shanghai Health Commission Implements Strict Guidelines to Curb Medical Sector Misconduct
The Shanghai Municipal Health Commission has issued the “Implementation Rules for the Nine Guidelines for...
China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus
The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...
Beijing Unveils Comprehensive Measures to Boost Innovative Medicine Development
The Beijing Municipal Medical Insurance Bureau, in conjunction with eight other bureaus, has announced a...
Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth
In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and...
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...
China’s National Joint Procurement Office Unveils Renewed Insulin Procurement Contracts
The National Joint Procurement Office in China announced the upcoming renewal of drug procurement contracts...
Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries
Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost...
Abiomed Recalls Over 66,000 Impella Heart Pumps Due to Serious Injury Risk, FDA Classifies as Class I Event
Johnson & Johnson (J&J, NYSE: JNJ), already embroiled in lawsuits over alleged cancer risks associated...
WuXi AppTec Denies US Allegations of Unauthorized Intellectual Property Transfer
WuXi AppTec (SHA: 603259, HKG: 2359), a leading Contract Research, Development, and Manufacturing Organization (CRDMO)...
China’s National Joint Procurement Office Announces Renewal of Insulin Procurement Contracts Valued at $1.59 Billion
The National Joint Procurement Office in China has announced the renewal of drug procurement contracts...
FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy
The US Food and Drug Administration (FDA) has given the green light to review an...